Amendments to Specification

Please replace the paragraph at page 2, lines 19-23 with the following:

or the (R) or (S) enantiomer thereof, or the *cis* or *trans* isomer thereof, or a pharmaceutically acceptable salt, solvate or prodrug thereof or of any of the foregoing, wherein m is 0 or 1; Z is



wherein R^7 is hydrogen or $(C_1$-$C_3)$alkoxy; R^8 is hydrogen, hydroxy, or $(C_1$-$C_3)$alkoxy; and R^9 is $(C_1$-$C_3)$alkyl;

Please replace the paragraph at Page 3, line 21 spanning to page 4, line 3 with the following:

or the (R) or (S) enantiomer thereof, or the *cis* or *trans* isomer thereof, or a pharmaceutically acceptable salt, solvate or prodrug thereof or of any of the foregoing, wherein Z is



wherein R^7 is hydrogen or $(C_1$-$C_3)$alkoxy; R^8 is hydrogen, hydroxy, or $(C_1$-$C_3)$alkoxy, and R^9 is $(C_1$-$C_3)$alkyl;

Please replace the paragraph at page 14, lines 16-20 with the following:

as a racemate, or the (R) and (S) enantiomers thereof, or the *cis* and *trans* isomers thereof, wherein X is oxygen or NR, wherein R is hydrogen or $(C_1\text{-}C_6)$alkyl;
R^1 and R^2 are each independently as hereinbefore defined and



wherein R^7 is hydrogen or $(C_1\text{-}C_3)$alkoxy; R^8 is hydrogen, hydroxy, or $(C_1\text{-}C_3)$alkoxy; and R^9 is $(C_1\text{-}C_3)$alkyl.

Please replace the consecutive paragraphs on Page 33, lines 11-17 with the following:

Example 4

(7R, 9aS)-*trans*- 1-(1-{6-[2-(5-Fluoro-benzo[d]isoxazol-3-yl)-octahydro-pyrido[1,2-a]pyrazin-7-ylmethoxy]-pyridin-2-ylmethyl}-4-phenyl-piperidin-4-yl) ethanone.

Starting material: 4-acety[[,]]l-4-phenylpiperdine. RT = 7.78 min. MS m/z 597.1.

Example 5

(7R, 9aS)-*trans*- (1,2-Dimethyl-propyl)-{6-[2-(5-fluoro-benzo[d]isoxazol-3-yl)-octahydro- **pyrido[1,2-a]pyrazin-7-ylmethoxy]-pyridin-2-ylmethyl}-amine.**

Please replace the paragraph at Page 56, line 29 with the following:

Example 56

[[(7S, 9aS)-cis]] (7R,9aS)-*trans*-7-(5-Azetidin-1-ylmethyl-pyridin-2-yloxymethyl)-2-benzo[d]isoxazol-3-yl-octahydro-pyrido[1,2-a]pyrazine

Please replace the paragraph at Page 56, lines 3 to 10 with the following:

Example 74

(7S, 9aS)-cis-[6-(2-Benzo[d]isoxazol-3-yl-octahydro-pyrido[1,2-a]pyrazin-7-ylmethoxy)-pyridin-3-ylmethyl]-ethyl-methyl-amine

Following the general procedure described in Step 2 of Example 72 and using **2-chloro-5-piperidin-1-ylmethyl-pyridine**. The reaction provided 1.0 g (87% yield) of 1-(6-Chloro-pyridin-3-ylmethyl)-methylethylamine. Diagnostic ^{1}H NMR (400 MHz, $CDCl_3$) 1.06 (t, 3H, J = 7.1 Hz), 2.14 (s, 3H), 2.40 (q, 2H, J = 7.1 Hz), 3.43 (s, 2H), 7.25 (d, 1H, J = 8.2 Hz), 7.62 (dd, 1H, J = 8.2 and 5.8Hz); MS (187.2 (M+H).

Please replace the paragraph at Page 67, lines 30 to 36 with the following:

To a solution of (7R, 9aS)-trans-methanesulfonic acid 6-(2-benzo[d]isoxazol-3-yl-octahydro-pyrido[1,2-a]pyrazin-7-ylmethoxy)-pyridin-2-ylmethyl ester (59 mg, 0.13 mmol) prepared as in example [[39]]**40**, step 4 and pyrrolidinone (36 mg, 0.5 mmol) in acetonitrile (3 ml) was stirred at 50°C for 8 hours. After cooling, the solvent is removed and the residue purified by flash chromatography to afford the title compound (35 mg, 64 %). Diagnostic ^{1}H NMR (400 MHz, $CDCl_3$) 1.16-1.23 (m, 1H), 1.32-1.42 (m, 1H), 1.69-1.72 (m, 1H), 1.86-1.95 (m, 4H), 2.14-2.20 (m, 2H), 2.45-2.51 (m, 1H), 2.79-3.06 (m, 5H), 3.08-3.10 (m, 1H), 3.25-3.32 (m,

Please replace the paragraph at Page 72, lines 1 to 9 with the following:

To a solution of (7R, 9aS)-trans-methanesulfonic acid 6-(2-benzo[d]isoxazol-3-yl-octahydro-pyrido[1,2-a]pyrazin-7-ylmethoxy)-pyridin-2-ylmethyl ester (0.16 mmol, 80 mg) prepared as in example [[39]]**40**, step 4 and 4-(2-aminotheyl)morpholine (75 mg, 0.5 mmol) in acetonitrile (3 ml) was stirred at 60°C for 7 hours. After cooling, the solvent is removed and the residue purified by flash chromatography to afford the title compound (18 mg, 22%). Diagnostic ^{1}H NMR (400 MHz, $CDCl_3$) 3.64-3.88 (m, 7H), 4.06 (dd, 1H, J = 10.8 and 7.4 Hz), 4.18 (dd, 1H, J = 10.8 and 5.4 Hz), 6.60 (d, 1H, J = 8.3 Hz), 6.83 (d, 1H, J = 7.0 hz), 7.18-7.23 (m, 1H), 7.30 (dd, 1H, J = 8.3 and 2.5 Hz), 7.36 (dd, 1H, J = 9.2 and 4.2 Hz), 7.51 (dd, 1H, J = 7.9 and 7.1 Hz); MS m/z 525.4(M+1).